Craneware’s 340B timing shock masks a resilient 90%-recurring SaaS franchise, with £26.12 probability-weighted five-year value versus a £12.14 share price.
Overview
Craneware plc is a specialist US healthcare software provider headquartered in Edinburgh, with revenue generated exclusively in the United States. Its Trisus platform helps hospitals manage revenue integrity, pricing compliance, billing analytics and 340B pharmacy procurement. The model is unusually defensive: approximately 90% of revenue is recurring SaaS subscription revenue, generally contracted for three to five years, and customer retention has remained above 90%. Craneware serves approximately 40% of US hospitals, more than 2,000 hospitals and nearly 10,000 clinics and pharmacies, while its solutions identified over $1.5 billion of customer revenue savings in FY25. **The investment case rests on a temporary 340B conversion delay being mispriced as permanent demand destruction.** FY26 guidance was reduced to $205–208 million of revenue and $65–67 million of adjusted EBITDA, broadly flat against FY25, after $500 million of qualifying purchases failed to convert before year-end and some enterprise contracts moved into FY27. At £12.14, the stock trades on 14.0x forward P/E despite 87% recurring gross margins and 32% EBITDA margins. **The principal catalysts are deferred 340B conversion, enterprise contract wins, audited FY26 results in September 2026 and recovery from the cybersecurity overhang.**